This article is more than 5 years old. Information may no longer be current.
VIDEO: Gregg W. Stone, MD, highlights advances in care for patients with ACS
CHICAGO —Gregg W. Stone, MD, of Columbia University Medical Center/New York-Presbyterian Hospital, an Editorial Board member for Cardiology Today’s Intervention, highlights new information on optimizing treatment for patients with ACS — in the settings of both non-STEMI and STEMI — that came out of the annual ACC Scientific Session.
“Interestingly, the late-breaking trials have not in any major way advanced care,” he said.
Stone discusses findings on deferred stenting from DANAMI 3-DEFER and ischemic post-conditioning from DANAMI 3-iPOST, emphasizing the negative trials demonstrate how far the field has come in improving patient care and underscoring one large limitation remaining.
He talks about the use of pharmacologic therapies to support patients with ACS undergoing early intervention including bivalirudin (Angiomax, The Medicines Company), P2Y12 receptor antagonist cangrelor (Kengreal, The Medicines Company) and duration of dual antiplatelet therapy, then touches on preferred stenting options, covering the standard metallic drug-eluting types and the new bioresorbable scaffold.